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The COVID-19 outbreak has caused a high mortality, with 
millions of people affected worldwide. COVID-19 infection 
has been reported to cause respiratory, enteric, hepatic, and 
neurological and neuropsychiatric complications with varied 
clinical severity.1 The prophylactic and treatment measures 
used for this disease varies by countries, and the World Health 
Organization (WHO) has also suggested other strategies to 
avoid the spread and management of COVID-19.2 The etiol-
ogy of COVID-19 is still mostly unknown. Therefore, identi-
fying the mechanisms that promote viral transmission and 
disease infection is critical in order to overcome this pandemic 
situation.3 Furthermoreuntil, Mnow there are no vaccines or 
therapeutic drugs available for COVID-19. Multiple drugs 
that may provide non-specific action, namely antiviral drugs 
(eg, remdesivir) and antimalarial drugs (eg, chloroquine and 
hydroxychloroquine), are being clinically screened for treat-
ment of COVID-19 patients. Systemic complications related 
to COVID-19 infection are being treated with therapeutic 
drugs such as corticosteroid (dexamethasone) or biological 
agents (antibodies) against the cytokine storm (interleukins: 
IL-1 and IL-6, and TNF-α). Kinase inhibitors are also being 
tried.4 Until the development of vaccines and better therapeu-
tics,  there is an urgent need for strategies to control respiratory 
infection and to boost immune functions for patients suffering 
from COVID-19.5,6
L-tryptophan (Trp), an essential amino acid, is the precursor 
of the neurotransmitter serotonin (5-hydroxytryptamine, 
5-HT), which promotes a sense of well-being and “happiness”, 
and plays a role in preventing mood disorders. Dietary fatty 
acids affecting the pro-inflammatory cytokines have been sug-
gested to affect the metabolic fate of Trp. Tryptophan and its 
metabolites including melatonin have the capacity to improve 
the immune system and reduce inflammation in various 
conditions.7-9 Here, we discuss the potential of using trypto-
phan and its metabolites including melatonin to boost the 
immune system in fighting COVID-19 infection (see Figure 1).
A recent study by Gardinassi et al,3 revealed a high involve-
ment of inflammatory networks and increased expression of 
genes involved in tryptophan metabolism in COVID19 patients. 
There is a definite involvement of interleukin-6 (IL-6) in the 
immune response in COVID-1910 and IL-6 is thought to affect 
tryptophan catabolism in other pathophysiological condi-
tions.11-13 Similarly, another study suggested a link between 
immunosuppressive therapy with tocilizumab and tryptophan 
metabolism in COVID-19 patients.14 This possibility indicates 
that tryptophan-rich sources could be beneficial for COVID-19 
subjects.15 Despite enormous efforts to develop a COVID-19 
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Figure 1. Tryptophan and its possible actions.
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vaccine, an effective and safe will, vaccine will likely not be avail-
able before 2021, which further demonstrates the need to 
develop quickly alternative solutions that are effective and known 
to be safe. Increasing evidence from several studies show that 
tryptophan and its metabolites including melatonin can reduce 
inflammatory reactions and enhance the immune system.7-9 
There may also be a possibility that serotonin levels are altered in 
COVID-19 patients because of mental stress, which suggest a 
role for Trp in treatment. Trp is the precursor for melatonin 
(sleep hormone), which was reported to exert beneficial effects 
on the immune system through various physiological means16 
(see Figure 2—adapted from Khan et al).17
In conclusion, even though Trp and its metabolites are 
known to be beneficial in improving the function of the 
immune system, the impact of Trp and its metabolites against 
severity of COVID-19 is still circumstantial and still needs to 
be demonstrated experimentally and clinically and to under-
stand their role in personalized nutrition thus precision health 
to combat COVID-19.
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